companies

Camena Bioscience

Founded 2016
Employees 15+
Primary contact
The Science Village
Chesterford Research Park
CB10 1XL Cambridge
United Kingdom
Links
https://www.camenabio.com/
Sections
Camena Bioscience is a synthetic biology company with novel DNA synthesis technology. Built on over seven years of innovation and with deep insight into the challenges faced in the pharmaceutical and biotechnology industries, their pioneering platform gSynth is rewriting the possibilities of DNA synthesis by unlocking access to genes with unparalleled accuracy and speed. Over 300 bp gSynth produces DNA with 90% accuracy, whereas the existing phosphoramidite DNA synthesis technology is just ~30% accurate and produces significant organic solvent waste. Camena offers an unmatched solution to gene production that simplifies complex supply chains and minimizes environmental impact.
Founded 2016
Employees 15+
Primary contact
The Science Village
Chesterford Research Park
CB10 1XL Cambridge
United Kingdom
Links
https://www.camenabio.com/
Sections

Funding 💰

Total $10M
Last round 🔗 $10M
Series A
July 3, 2023.
Select investors Mercia Asset Management

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Solution for complex gene production: The ability to read, write, and manipulate DNA is essential for synthetic biologists to investigate and engineer biological pathways. Yet existing nucleic acid synthesis technology is error-prone, and some specific DNA sequences are particularly difficult to produce. Camena's innovative technology has turned that on its head. Called gSynth, its synthesis technology will enable a range of different applications - enabling biology companies to solve problems that are currently intractable. 🔗
  • Helping drug discovery: Camena Bioscience's gSynth platform uses a multi-enzymatic and modular assembly approach. As such, it is reliable for accurately producing long synthetic DNA, RNA and XNA molecules, which will aid the development of new therapeutics. 🔗
  • Already making money: The company has already signed commercial agreements with leading consumers of synthetic genes, securing a multi-million-pound revenue stream over the previous year.

Video ▶️

In the news 📰

Camena Bioscience raises $10M Series A for its DNA synthesis platform
July 3, 2023

Quotes 💬

“
The market for synthetic genes is growing rapidly but much of the demand is for complex genes which are extremely difficult to produce accurately. Camena's technology is a game changer that could unlock a much bigger global market. We're excited to support Camena on its next stage of growth.
— Lee Lindley, Investment Manager at Mercia 🔗
Last update: July 11, 2023